245 related articles for article (PubMed ID: 36139695)
1. MicroRNA-34a, Prostate Cancer Stem Cells, and Therapeutic Development.
Li WJ; Liu X; Dougherty EM; Tang DG
Cancers (Basel); 2022 Sep; 14(18):. PubMed ID: 36139695
[TBL] [Abstract][Full Text] [Related]
2. MicroRNA-34a: Potent Tumor Suppressor, Cancer Stem Cell Inhibitor, and Potential Anticancer Therapeutic.
Li WJ; Wang Y; Liu R; Kasinski AL; Shen H; Slack FJ; Tang DG
Front Cell Dev Biol; 2021; 9():640587. PubMed ID: 33763422
[TBL] [Abstract][Full Text] [Related]
3. Developing Folate-Conjugated miR-34a Therapeutic for Prostate Cancer: Challenges and Promises.
Li WJ; Wang Y; Liu X; Wu S; Wang M; Turowski SG; Spernyak JA; Tracz A; Abdelaal AM; Sudarshan K; Puzanov I; Chatta G; Kasinski AL; Tang DG
Int J Mol Sci; 2024 Feb; 25(4):. PubMed ID: 38396800
[TBL] [Abstract][Full Text] [Related]
4. Developing folate-conjugated miR-34a therapeutic for prostate cancer treatment: Challenges and promises.
Li WJ; Wang Y; Liu X; Wu S; Wang M; Turowski SG; Spernyak JA; Tracz A; Abdelaal AM; Sudarshan K; Puzanov I; Chatta G; Kasinski AL; Tang DG
bioRxiv; 2024 Jan; ():. PubMed ID: 38045265
[TBL] [Abstract][Full Text] [Related]
5. Inactivation of AR and Notch-1 signaling by miR-34a attenuates prostate cancer aggressiveness.
Kashat M; Azzouz L; Sarkar SH; Kong D; Li Y; Sarkar FH
Am J Transl Res; 2012; 4(4):432-42. PubMed ID: 23145211
[TBL] [Abstract][Full Text] [Related]
6. Erratum: Epigenetic silencing of miR-34a in human prostate cancer cells and tumor tissue specimens can be reversed by BR-DIM treatment.
Kong D; Heath E; Chen W; Cher M; Powell I; Heilbrun L; Li Y; Ali S; Sethi S; Hassan O; Hwang C; Gupta N; Chitale D; Sakr W; Menon M; Sarkar F
Am J Transl Res; 2013; 6(1):102-103. PubMed ID: 24349627
[TBL] [Abstract][Full Text] [Related]
7. Epigenetic silencing of miR-34a in human prostate cancer cells and tumor tissue specimens can be reversed by BR-DIM treatment.
Kong D; Heath E; Chen W; Cher M; Powell I; Heilbrun L; Li Y; Ali S; Sethi S; Hassan O; Hwang C; Gupta N; Chitale D; Sakr WA; Menon M; Sarkar FH
Am J Transl Res; 2012; 4(1):14-23. PubMed ID: 22347519
[TBL] [Abstract][Full Text] [Related]
8. Chitosan nanoparticle-mediated delivery of miRNA-34a decreases prostate tumor growth in the bone and its expression induces non-canonical autophagy.
Gaur S; Wen Y; Song JH; Parikh NU; Mangala LS; Blessing AM; Ivan C; Wu SY; Varkaris A; Shi Y; Lopez-Berestein G; Frigo DE; Sood AK; Gallick GE
Oncotarget; 2015 Oct; 6(30):29161-77. PubMed ID: 26313360
[TBL] [Abstract][Full Text] [Related]
9. Androgen receptor and prostate cancer stem cells: biological mechanisms and clinical implications.
Deng Q; Tang DG
Endocr Relat Cancer; 2015 Dec; 22(6):T209-20. PubMed ID: 26285606
[TBL] [Abstract][Full Text] [Related]
10. Androgen receptor (AR) heterogeneity in prostate cancer and therapy resistance.
Jamroze A; Chatta G; Tang DG
Cancer Lett; 2021 Oct; 518():1-9. PubMed ID: 34118355
[TBL] [Abstract][Full Text] [Related]
11. The microRNA miR-34a inhibits prostate cancer stem cells and metastasis by directly repressing CD44.
Liu C; Kelnar K; Liu B; Chen X; Calhoun-Davis T; Li H; Patrawala L; Yan H; Jeter C; Honorio S; Wiggins JF; Bader AG; Fagin R; Brown D; Tang DG
Nat Med; 2011 Feb; 17(2):211-5. PubMed ID: 21240262
[TBL] [Abstract][Full Text] [Related]
12. The evolving landscape of prostate cancer stem cell: Therapeutic implications and future challenges.
Yun EJ; Lo UG; Hsieh JT
Asian J Urol; 2016 Oct; 3(4):203-210. PubMed ID: 29264188
[TBL] [Abstract][Full Text] [Related]
13. MicroRNA expression signature of castration-resistant prostate cancer: the microRNA-221/222 cluster functions as a tumour suppressor and disease progression marker.
Goto Y; Kojima S; Nishikawa R; Kurozumi A; Kato M; Enokida H; Matsushita R; Yamazaki K; Ishida Y; Nakagawa M; Naya Y; Ichikawa T; Seki N
Br J Cancer; 2015 Sep; 113(7):1055-65. PubMed ID: 26325107
[TBL] [Abstract][Full Text] [Related]
14. Epigallocatechin-3-gallate Enhances the Efficacy of MicroRNA-34a Mimic and MicroRNA-93 Inhibitor Co-transfection in Prostate Cancer Cell Line.
Mokhtari H; Yaghmaei B; Sirati-Sabet M; Jafari N; Mardomi A; Abediankenari S; Mahrooz A
Iran J Allergy Asthma Immunol; 2020 Dec; 19(6):612-623. PubMed ID: 33463130
[TBL] [Abstract][Full Text] [Related]
15. Ultrasound-Induced Microbubble Cavitation Combined with miR-34a-Loaded Nanoparticles for the Treatment of Castration-Resistant Prostate Cancer.
Wang Z; Chen C; Tao Y; Zou P; Gao F; Jia C; Liu L; Li G; Zhang G; Duan Y; Shi Q
J Biomed Nanotechnol; 2021 Jan; 17(1):78-89. PubMed ID: 33653498
[TBL] [Abstract][Full Text] [Related]
16. miR-27b and miR-34a enhance docetaxel sensitivity of prostate cancer cells through inhibiting epithelial-to-mesenchymal transition by targeting ZEB1.
Zhang G; Tian X; Li Y; Wang Z; Li X; Zhu C
Biomed Pharmacother; 2018 Jan; 97():736-744. PubMed ID: 29102917
[TBL] [Abstract][Full Text] [Related]
17. Targeting epigenetic regulation of miR-34a for treatment of pancreatic cancer by inhibition of pancreatic cancer stem cells.
Nalls D; Tang SN; Rodova M; Srivastava RK; Shankar S
PLoS One; 2011; 6(8):e24099. PubMed ID: 21909380
[TBL] [Abstract][Full Text] [Related]
18. Targeting Castration-Resistant Prostate Cancer Using Mesenchymal Stem Cell Exosomes for Therapeutic MicroRNA-let-7c Delivery.
Kurniawati I; Liu MC; Hsieh CL; Do AD; Sung SY
Front Biosci (Landmark Ed); 2022 Sep; 27(9):256. PubMed ID: 36224011
[TBL] [Abstract][Full Text] [Related]
19. Identification and validation of microRNAs that synergize with miR-34a - a basis for combinatorial microRNA therapeutics.
Orellana EA; Li C; Lisevick A; Kasinski AL
Cell Cycle; 2019 Aug; 18(15):1798-1811. PubMed ID: 31258013
[TBL] [Abstract][Full Text] [Related]
20. MicroRNA-mRNA Regulatory Network Mediates Activation of mTOR and VEGF Signaling in African American Prostate Cancer.
Gujrati H; Ha S; Mohamed A; Wang BD
Int J Mol Sci; 2022 Mar; 23(6):. PubMed ID: 35328346
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
